Literature DB >> 35597701

Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer.

Nasim Ebrahimi1, Sahar Parkhideh2, Setare Samizade3, Alireza Nasr Esfahani3, Sahar Samsami4, Elnaz Yazdani5, Samaneh Adelian6, Siavash Rahimian Chaleshtori7, Kamal Shah-Amiri6, Amirhossein Ahmadi8, Amir Reza Aref9.   

Abstract

The assertion that a significant portion of the mammalian genome has not been translated and that non-coding RNA accounts for over half of polyadenylate RNA have received much attention. In recent years, increasing evidence proposes non-coding RNAs (ncRNAs) as new regulators of various cellular processes, including cancer progression and nerve damage. Apoptosis is a type of programmed cell death critical for homeostasis and tissue development. Cancer cells often have inhibited apoptotic pathways. It has recently been demonstrated that up/down-regulation of various lncRNAs in certain types of tumors shapes cancer cells' response to apoptotic stimuli. This review discusses the most recent studies on lncRNAs and apoptosis in healthy and cancer cells. In addition, the role of lncRNAs as novel targets for cancer therapy is reviewed here. Finally, since it has been shown that lncRNA expression is associated with specific types of cancer, the potential for using lncRNAs as biomarkers is also discussed.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Biomarkers; Cancer therapy; LncRNAs; Therapeutic target

Mesh:

Substances:

Year:  2022        PMID: 35597701     DOI: 10.1016/j.cytogfr.2022.04.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  2 in total

1.  Editorial: Long-non coding RNAs in renal cell carcinoma.

Authors:  Zongping Wang; Song Wang; An Zhao
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

2.  Knockdown of Long Noncoding RNA LINC00240 Inhibits Esophageal Cancer Progression by Regulating miR-26a-5p.

Authors:  Yupeng Liu; Tao Li; Chunlei Peng; Qinghua Mao; Biao Shen; Minxin Shi; Haimin Lu; Ting Xiao; Aimin Yang; Chun Cheng
Journal:  Contrast Media Mol Imaging       Date:  2022-10-05       Impact factor: 3.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.